Losartan Potassium Tablet, Film Coated
Product Images NDC 63187-708

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 63187-708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

63187-708-90 (Losartan100mg30s)

Losartan Potassium 100 mg film coated tablets carton label by Proficient Rx LP. The label shows the product as prescription only, containing 30 tablets. Each tablet contains 100 mg of losartan potassium USP. Tablets are described as white to off-white, film coated, teardrop shaped with specific debossing. Manufactured by Hetero Labs Limited, India, with storage instructions of 20°-25°C (68°-77°F). The label includes multiple markings, lot, expiration placeholders, and barcodes.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over 60 study months for Losartan Potassium and Atenolol. The graph shows a gradual increase for both, with Losartan Potassium having a lower percentage throughout. Adjusted risk reduction is noted as 13% with a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line chart comparing the percentage of patients with fatal/non-fatal stroke over study months between Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0% to 8%. Atenolol is represented by a dotted line, and Losartan Potassium by a solid line, with Losartan showing a lower percentage over time. The chart includes an adjusted risk reduction of 25% with p=0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure presenting primary endpoint events comparing Losartan Potassium and Atenolol within demographic subgroups. It shows event rates (%) and hazard ratios (95% CI) for primary composite outcomes and fatal/non-fatal strokes by age, gender, race, ISH status, diabetes, and history of cardiovascular disease across 8183 patients.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph showing the percentage of patients with an event over 48 months comparing Losartan Potassium and placebo. The graph illustrates risk reduction and statistical significance with a p-value noted.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of Losartan Potassium showing its molecular framework including a biphenyl component, a tetrazole ring, and other characteristic groups. The image represents the active ingredient Losartan Potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.